Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats - PubMed (original) (raw)

. 2005 Nov;315(2):688-95.

doi: 10.1124/jpet.105.087064. Epub 2005 Jul 18.

Affiliations

• PMID: 16027230
• DOI: 10.1124/jpet.105.087064

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

B F Burkey et al. J Pharmacol Exp Ther. 2005 Nov.

Abstract

The enzyme dipeptidyl peptidase-IV (DPP-4) inactivates the incretin hormone glucagon-like peptide-1 (GLP-1). Because GLP-1 has therapeutic effects in patients with type 2 diabetes, but its potential is limited by a short half-life, DPP-4 inhibition is a promising approach to diabetes treatment. This study examined acute (single dose) and chronic (once-a-day dosing for 21 days) effects of the DPP-4 inhibitor vildagliptin (0.03-10 mg/kg) on plasma DPP-4 activity, intact GLP-1, glucose, and insulin after an oral glucose load in insulin-resistant Zucker fatty rats and acute effects in mildly insulin-resistant high-fat-fed normal rats. A single oral dose of vildagliptin in Zucker rats produced a rapid and dose-related inhibition of DPP-4: the minimum effective dose (MED) was 0.3 mg/kg. Glucose-induced increases of intact GLP-1 were greatly but similarly enhanced by vildagliptin at doses > or =0.3 mg/kg. Postload glucose excursions decreased, and the insulinogenic index (Deltainsulin/Deltaglucose at 10 min) increased, with an MED of 0.3 mg/kg and a maximally effective dose of 3 mg/kg. The effects of vildagliptin after chronic treatment were nearly identical to those of acute administration, and vildagliptin had no effect on body weight. In fat-fed normal rats, vildagliptin (3 mg/kg) also decreased postload glucose excursions and increased the insulinogenic index, but these effects were smaller than those in Zucker rats. Thus, vildagliptin is an orally effective incretin enhancer with antihyperglycemic activity in insulin-resistant rats and exhibits no tachyphylaxis. GLP-1-mediated augmentation of glucose-induced insulin release seems to make the major contribution to the antidiabetic properties of vildagliptin.

PubMed Disclaimer

Similar articles

• 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
  Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I. Yamazaki K, et al. J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. doi: 10.1124/jpet.106.112805. Epub 2006 Sep 15. J Pharmacol Exp Ther. 2006. PMID: 16980568
• Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
  Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Rosenstock J, et al. Diabetes Care. 2008 Jan;31(1):30-5. doi: 10.2337/dc07-1616. Epub 2007 Oct 18. Diabetes Care. 2008. PMID: 17947341 Clinical Trial.
• The role of vildagliptin in the management of type 2 diabetes mellitus.
  Kleppinger EL, Helms K. Kleppinger EL, et al. Ann Pharmacother. 2007 May;41(5):824-32. doi: 10.1345/aph.1H460. Epub 2007 Apr 24. Ann Pharmacother. 2007. PMID: 17456545 Review.
• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
  Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA. Bergman AJ, et al. Clin Ther. 2006 Jan;28(1):55-72. doi: 10.1016/j.clinthera.2006.01.015. Clin Ther. 2006. PMID: 16490580 Clinical Trial.
• The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
  Ahrén B, Foley JE. Ahrén B, et al. Int J Clin Pract Suppl. 2008 Mar;(159):8-14. doi: 10.1111/j.1742-1241.2007.01685.x. Int J Clin Pract Suppl. 2008. PMID: 18269436 Review.

Cited by

• Natural Drugs: A New Direction for the Prevention and Treatment of Diabetes.
  Wu P, Wang X. Wu P, et al. Molecules. 2023 Jul 20;28(14):5525. doi: 10.3390/molecules28145525. Molecules. 2023. PMID: 37513397 Free PMC article. Review.
• Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress.
  Aghahoseini F, Alihemmati A, Hosseini L, Badalzadeh R. Aghahoseini F, et al. J Diabetes Metab Disord. 2020 Jun 4;19(2):701-707. doi: 10.1007/s40200-020-00548-7. eCollection 2020 Dec. J Diabetes Metab Disord. 2020. PMID: 33553010 Free PMC article.
• Bornyl Derivatives of _p_-(Benzyloxy)Phenylpropionic Acid: In Vivo Evaluation of Antidiabetic Activity.
  Kuranov S, Luzina O, Khvostov M, Baev D, Kuznetsova D, Zhukova N, Vassiliev P, Kochetkov A, Tolstikova T, Salakhutdinov N. Kuranov S, et al. Pharmaceuticals (Basel). 2020 Nov 19;13(11):404. doi: 10.3390/ph13110404. Pharmaceuticals (Basel). 2020. PMID: 33228030 Free PMC article.
• DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism.
  Furukawa N, Koitabashi N, Matsui H, Sunaga H, Umbarawan Y, Syamsunarno MRAA, Yamaguchi A, Obokata M, Hanaoka H, Yokoyama T, Kurabayashi M. Furukawa N, et al. Heart Vessels. 2021 Jan;36(1):136-146. doi: 10.1007/s00380-020-01711-z. Epub 2020 Oct 18. Heart Vessels. 2021. PMID: 33073318 Free PMC article.
• Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats.
  Aulinger BA, Perabo M, Seeley RJ, Parhofer KG, D'Alessio DA. Aulinger BA, et al. Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E189-E197. doi: 10.1152/ajpendo.00298.2019. Epub 2019 Nov 19. Am J Physiol Endocrinol Metab. 2020. PMID: 31743041 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • HighWire

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal